Yichang Renfu Pharmaceutical’s extended-release venlafaxine succinate tablets have been approved for market launch.

Release time:

2025-02-28 13:46

Source:

Recently, Yichang Renfu Pharmaceutical’s extended-release venlafaxine succinate tablets have received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. This product has been approved for marketing under Category 3 of chemical drugs, with the approved indication being the treatment of major depressive disorder (MDD) in adults. The available strengths are 25mg, 50mg, and 100mg, and it is considered to have passed the consistency evaluation.

Depression is a chronic mental disorder characterized by a high incidence rate, a high relapse rate, a high suicide rate, and a high disability rate. It can affect individuals at nearly any age. Since the onset of the COVID-19 pandemic, the global number of new depression cases has exceeded 70 million. According to data from the World Health Organization, the global number of people living with depression has now reached 350 million. According to statistics from the "2022 National Blue Book on Depression," the number of people suffering from depression in China is approximately 95 million, and the age of onset is trending younger, with individuals under the age of 18 accounting for 30% of the total depressed population.
Venlafaxine succinate is a third-generation antidepressant that exerts a dual antidepressant effect by inhibiting the reuptake of serotonin and norepinephrine, thereby increasing their concentrations. It is a widely used antidepressant worldwide.
The approval and launch of Yichang Renfu Pharmaceutical’s extended-release venlafaxine succinate tablets further enrich the company’s product lineup in the psychoneurological field. The company will subsequently actively promote the launch and sales of this product, providing patients with depression a wider range of treatment options.

Yichang Renfu Pharmaceutical’s Class 1 new chemical drug, CXJM-66 Injection, has been approved for clinical trials.

Renfu Pharmaceutical Group has been awarded the title of “Outstanding Corporate Social Responsibility Enterprise in the Yangtze River Economic Belt (Hubei Region).”

Trending News

Accelerating the layout for independent production of innovative drugs: The construction of Renfu Pharmaceutical’s innovative drug industrial base has begun.

Yichang Renfu Pharmaceutical’s Bupropion Hydrochloride Extended-Release Tablets (XL) Approved for Marketing in Canada

Yichang Renfu Pharmaceutical has been selected as an Excellence-Level Smart Factory for 2025.

Yichang Renfu Pharmaceutical won second and third prizes in the finals of the China Innovation Methods Competition.

Deng Renjie Conducts a Survey of Renfu Pharmaceutical

Tide of Innovation and Entrepreneurship, Pursuing Dreams Together | The 22nd Corporate Day of China Merchants Group and the 2025 Employee Badminton and Basketball Tournament of Renfu Pharmaceutical Were Successfully Held.

Corporate culture

Make drug launches safer and faster, and ensure the tree of life remains evergreen.

Learn more